Céline Halluard

573 total citations
7 papers, 303 citations indexed

About

Céline Halluard is a scholar working on Genetics, Oncology and Epidemiology. According to data from OpenAlex, Céline Halluard has authored 7 papers receiving a total of 303 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Genetics, 3 papers in Oncology and 3 papers in Epidemiology. Recurrent topics in Céline Halluard's work include Virus-based gene therapy research (4 papers), Immunotherapy and Immune Responses (2 papers) and vaccines and immunoinformatics approaches (1 paper). Céline Halluard is often cited by papers focused on Virus-based gene therapy research (4 papers), Immunotherapy and Immune Responses (2 papers) and vaccines and immunoinformatics approaches (1 paper). Céline Halluard collaborates with scholars based in France, Poland and United States. Céline Halluard's co-authors include Bruce Acres, Jean‐Marc Limacher, Éric Tartour, Miklos Pless, Rodryg Ramlau, Éric Levy, Marie‐Pierre Chenard, H. Léna, Maciej Krzakowski and Thierry Velu and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Radiation Oncology*Biology*Physics and Annals of Oncology.

In The Last Decade

Céline Halluard

7 papers receiving 299 citations

Peers

Céline Halluard

IMMUN

ONCOL

MB

GENET

EPIDE

Kaïdre Bendjama France

Adina Pelusio South Korea

Guillemette Masse‐Ranson France

Maurizio Nuzzo Italy

Martino Böhne Netherlands

Angela Mauriello Italy

Daniel Shu United States

Sarah Knocke Germany

Susan Strobl United States

Teis Jensen Denmark

Kaïdre Bendjama France

Céline Halluard

148 ×1.0

IMMUN

113 ×0.8

ONCOL

107 ×0.9

MB

36 ×0.5

GENET

72 ×0.9

EPIDE

Citations per year, relative to Céline Halluard Céline Halluard (= 1×) peers Kaïdre Bendjama

Countries citing papers authored by Céline Halluard

Since Specialization

Citations

This map shows the geographic impact of Céline Halluard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Céline Halluard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Céline Halluard more than expected).

Fields of papers citing papers by Céline Halluard

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Céline Halluard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Céline Halluard. The network helps show where Céline Halluard may publish in the future.

Co-authorship network of co-authors of Céline Halluard

This figure shows the co-authorship network connecting the top 25 collaborators of Céline Halluard. A scholar is included among the top collaborators of Céline Halluard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Céline Halluard. Céline Halluard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

1.

Tourneau, Christophe Le, Frédéric Rolland, Olivier Capitain, et al.. (2025). Randomized phase II trial evaluating the combination of TG4001, an HPV16 therapeutic vaccine, and avelumab (ave) in patients (pts) with immunotherapy-naïve recurrent and/or metastatic (R/M) HPV16-positive cervical or anogenital cancer.. Journal of Clinical Oncology. 43(16_suppl). 2638–2638. 1 indexed citations

2.

Zoulim, Fabien, François Habersetzer, Martin F. Sprinzl, et al.. (2019). Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial. Human Vaccines & Immunotherapeutics. 16(2). 388–399. 66 indexed citations

3.

Delord, Jean‐Pierre, Jérôme Guitton, Philippe Erbs, et al.. (2016). Vectorized gene therapy of liver tumors: proof-of-concept of TG4023 (MVA-FCU1) in combination with flucytosine. Annals of Oncology. 28(1). 169–174. 27 indexed citations

4.

Quoix, Élisabeth, György Losonczy, Frédéric Forget, et al.. (2014). TIME, a Phase 2b/3 Study Evaluating TG4010 in Combination With First-Line Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC): Phase 2b Results. International Journal of Radiation Oncology*Biology*Physics. 90(5). S35–S35. 2 indexed citations

5.

Delord, Jean‐Pierre, Jean‐Emmanuel Kurtz, Philippe Erbs, et al.. (2012). Vectorized gene therapy of liver tumors: Safety and proof of concept of TG4023 (MVA-FCU1)/5-FC combination.. Journal of Clinical Oncology. 30(15_suppl). 2605–2605. 1 indexed citations

6.

Ramlau, Rodryg, Élisabeth Quoix, Janusz Rolski, et al.. (2008). A Phase II Study of Tg4010 (Mva-Muc1-Il2) in Association with Chemotherapy in Patients with Stage III/IV Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 3(7). 735–744. 162 indexed citations

7.

Braun, Serge, Christine Thioudellet, Dalila Ali-Hadji, et al.. (2000). Immune rejection of human dystrophin following intramuscular injections of naked DNA in mdx mice. Gene Therapy. 7(17). 1447–1457. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact